A Phase II Efficacy Trial of Pazopanib in Non-Clear Cell Metastatic Renal Cell Cancer (mRCC) PINCR

Trial Profile

A Phase II Efficacy Trial of Pazopanib in Non-Clear Cell Metastatic Renal Cell Cancer (mRCC) PINCR

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2018

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Feb 2018 Status changed from recruiting to active, no longer recruiting.
    • 07 Sep 2017 Status changed from suspended to recruiting.
    • 23 Aug 2017 Status changed from active, no longer recruiting to suspended.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top